Latest news with #Epichlorohydrin
Time of India
11-08-2025
- Business
- Time of India
Epigral expects derivatives & speciality products to contribute 70pc of revenue by FY28
Chemicals maker Epigral expects its derivatives and speciality product vertical to contribute over 70 per cent of the revenue by 2027-28 and play a major role in achieving the targeted 20 per cent annual growth, a top company official said. The new chemistry and focus on derivatives & specialty products will bring a lot of consistency in the revenue as well as profits, Epigral Chairman and Managing Director Maulik Patel said in a statement. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Patel said that the company's capex projects of doubling capacity of CPVC resin and Epichlorohydrin plant are moving as per the schedule and are expected to be commissioned within the time line and budget announced. "We expect this to strengthen our diversification and reach to a 70 per cent revenue contribution from the derivatives and specialty business. This expansion, along with Chlorotoluene value chain , which got commissioned in March 2025, are expected to drive growth in FY '27 and FY '28," he said. The company expects demand from the domestic market to drive its growth momentum in the long term. It is already investing in research and development capabilities to identify new chemistries with good growth potential in India, Patel said. Live Events Derivatives & speciality products accounted for 54 per cent of the total revenue in FY2024-25. Epigral is also the country's largest and only manufacturer of Epichlorohydrin and it is set to expand its Chlorinated Polyvinyl Chloride (CPVC) capacity from 75,000 MTPA to 1,50,000 MTPA, Patel said. The company expects that despite strong growth in revenue numbers, its EBITDA margin to remain at around 25 per cent on account ofa higher efficiency level and better product mix, he added. Epigral has reported revenue of Rs 615 crore for the quarter ended June 30, 2025, against Rs 654 crore in the same quarter of FY25. Its profit after tax stood at Rs 160 crore compared to Rs 86 crore in the June quarter of FY25.
&w=3840&q=100)
Business Standard
13-06-2025
- Business
- Business Standard
DCM Shriram to acquire Hindusthan Specialty Chem for ₹375 cr; stock up 3%
DCM Shriram share price: DCM Shriram shares were in demand on the last trading day of the week i.e. Friday, June 13, 2025, with the scrip rising up to 3.11 per cent to hit an intraday high of ₹1,159.95 per share. By 10:11 AM, DCM Shriram shares were off day's high and were trading flat with a negative bias, down 0.06 per cent at ₹1,124.25. In comparison, BSE Sensex was trading 1.11 per cent lower to 80,787.14 levels. Catch Stock Market Latest Updates Today LIVE Why did DCM Shriram rise in an overall weak market today? DCM Shriram shares jumped in trade after the Board of Directors of the company approved Definitive Agreements to be entered into for acquiring 100 per cent equity share capital of Hindusthan Speciality Chemicals Limited for ₹375 crore, in one or more tranches, subject to adjustments as per terms of Definitive Agreements. In an exchange filing, DCM Shriram said, 'We hereby inform you that the Board of Directors of the Company at its meeting held today, June 12, 2025 has, inter alia, approved Definitive Agreements to be entered into for acquiring 100 per cent equity share capital of 'Hindusthan Speciality Chemicals Limited', having presence in Epoxy & Advanced Materials business in Bharuch, Gujarat, subject to necessary regulatory approvals.' The acquisition also marked the entry of the chemicals business of DCM Shriram in the Epoxy & Advanced Materials space, as a downstream integration of Epichlorohydrin (ECH). DCM Shriram Q4 results DCM Shriram reported a 52 per cent year-on-year (Y-o-Y) rise in consolidated net profit to ₹178.91 crore for the March quarter (Q4FY25), supported by higher income. The company had posted a net profit of ₹117.80 crore in the same period last year (Q4FY24). Total income for the January–March quarter of FY24 rose to ₹3,040.60 crore from ₹2,555.23 crore a year ago. For the full fiscal year 2024-25, net profit grew to ₹604.27 crore compared to ₹447.10 crore in the previous year, while total income increased to ₹12,883.46 crore from ₹11,529.83 crore. ALSO READ | About DCM Shriram DCM Shriram is a diversified Indian conglomerate with a legacy dating back to 1889. It operates across multiple sectors including agri-rural, chemicals, and value-added businesses. The company's portfolio spans the production of urea, sugar, ethanol, and farm inputs, along with key industrial chemicals like caustic soda, chlorine, and PVC resins. A major player in the agri-rural sector, DCM Shriram is among India's leading sugar producers and is actively involved in renewable energy initiatives such as green power and ethanol production. In its value-added segment, the company operates Fenesta Building Systems, offering high-quality UPVC and aluminum windows and doors.
Business Standard
13-06-2025
- Business
- Business Standard
Stock Alert: Jubilant Pharmova, Canara Bank, Torrent Power, DCM Shriram, CSB Bank
Securities in F&O Ban: Aditya Birla Fashion & Retail (ABFRL), Birla Soft, Central Depository Services (CDSL), Chambal Fertilisers & Chemicals, Hindustan Copper, Indian Energy Exchange (IEX), Indian Renewable Energy Development Agency (IREDA), RBL Bank and Titagrah Rail Systems shares are banned from F&O trading on 11 June 2025. Stocks to Watch: Jubilant Pharmovas board approved the sale and transfer of its active pharmaceutical ingredients (API) business on a slump sale basis to Jubilant Biosys, a wholly-owned subsidiary. The API business of the company achieved turnover of Rs 609 crore, representing 8.35% of the consolidated turnover for the financial year ended 31st March 2025. Canara Banks board has approved the capital raising plan for the financial year 2025-26 amounting upto Rs 9,500 crore by way of debt instruments (Additional Tier I/Tier II Bonds). Torrent Powers wholly owned subsidiary, Torrent Green Energy has emerged as successful bidder under competitive bidding and has received letter of award from Solar Energy Corporation of India (SECI) on June 11, 2025 for setting up of 300 MW Wind power project under Wind Tranche-XVIII. The estimated investment for the project is Rs 2,650 crore. DCM Shrirams board has approved signing of a definitive agreement to acquire a 100% stake in wholly owned subsidiary, Hindusthan Speciality Chemicals for Rs 375 crore, to enter into Epoxy & Advanced Materials space, as a downstream integration of Epichlorohydrin (ECH). Dixon Technologies (India) has executed a joint venture agreement with Signify to enable formation of a joint venture company in India to carry on the OEM business of lighting products and accessories. The shareholding of the JV Co. will be held in equal proportion (50:50) by the Company and Signify CSB Bank announced that Reserve Bank of India (RBI) has approved the reappointment of Pralay Mondal as managing director & CEO of the bank for a period of three years with effect from September 15, 2025.
Time of India
07-06-2025
- Business
- Time of India
Epigral to expand wind-solar hybrid power plant to 38.14 MW, Manufacturing News, ET Manufacturing
Advt Specialty chemical manufacturer Epigral said on Wednesday it will more than double its wind-solar hybrid power capacity to 38.14 megawatt (MW) from 18.34 MW through a Rs 21.38-crore company will invest Rs 21.38 crore for a 26 per cent stake in a special purpose vehicle (SPV) created in partnership with Prozeal Green Energy Ltd to add 19.80 MW renewable strategic partnership will be formalised for 25 years through an energy subscription agreement and share subscription and shareholder agreement between the two companies, Epigral said in a capacity expansion is expected to be commissioned by the fourth quarter of FY26 and will help meet rising power demands from upcoming projects, the company said."The capacity expansion will be important to meet our rising energy demands," Epigral Chairman and Managing Director Maulik Patel has announced plans to expand capacity for CPVC Resin to 150,000 tonnes per annum and Epichlorohydrin (ECH) to 100,000 tonnes per annum. The company recently commissioned a chlorotoluene value chain plant at its Dahej facility in renewable energy expansion reflects the company's strategy to secure clean power while pursuing aggressive growth in the specialty chemicals sector
Time of India
07-06-2025
- Business
- Time of India
Epigral to expand wind-solar hybrid power plant to 38.14 MW
Specialty chemical manufacturer Epigral said on Wednesday it will more than double its wind-solar hybrid power capacity to 38.14 megawatt (MW) from 18.34 MW through a Rs 21.38-crore investment. The company will invest Rs 21.38 crore for a 26 per cent stake in a special purpose vehicle (SPV) created in partnership with Prozeal Green Energy Ltd to add 19.80 MW renewable capacity. The strategic partnership will be formalised for 25 years through an energy subscription agreement and share subscription and shareholder agreement between the two companies, Epigral said in a statement. The capacity expansion is expected to be commissioned by the fourth quarter of FY26 and will help meet rising power demands from upcoming projects, the company said. "The capacity expansion will be important to meet our rising energy demands," Epigral Chairman and Managing Director Maulik Patel said. Live Events Epigral has announced plans to expand capacity for CPVC Resin to 150,000 tonnes per annum and Epichlorohydrin (ECH) to 100,000 tonnes per annum. The company recently commissioned a chlorotoluene value chain plant at its Dahej facility in Gujarat. The renewable energy expansion reflects the company's strategy to secure clean power while pursuing aggressive growth in the specialty chemicals sector .
